Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02014883 | Phase II Open Label Study Using Triheptanoin in Patients With Glucose Type 1 Transporter Deficiency GLUT1-DS | PHASE2 | COMPLETED | 20 | — | — | Dec 4, 2013 | Jul 4, 2019 | Oct 3, 2025 | 1 | France |
The number of paroxystic events, in particular abnormal movements, will be collected during trihepatnoin treatment.
| Arm | Type | Description |
|---|---|---|
| GLUT1 DS | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| GLUT1 DS | DRUG | - |
Inclusion Criteria: * Mutation in SLC2A1 gene * Age \> 3 years * Patient with history/frequency of seizures or movement disorders documented at least 3 months prior to the beginning of the study * Covered by french social security * Patients who freely agree to participate in this study and underst...